NCT00423254 - Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

September 30, 2009

Study Completion Date

November 30, 2009

Conditions

OvarianMelanomaRenalProstateColorectalEndometrial CarcinomaCervical CarcinomaTesticular CancerThyroid CancerSmall Cell Lung CarcinomaMesotheliomaBreast CarcinomaEsophageal CarcinomaGastric CancerPancreatic CarcinomaNeuroendocrine CancerLiver CancerGallbladder CancerBiliary Tract CancerAnal CarcinomaBone SarcomasSoft Tissue SarcomasCarcinoma of Unknown Origin, Primary

Interventions

BIOLOGICAL

PSMA/PRAME

Low dose

BIOLOGICAL

PSMA/PRAME

high dose

Trial Locations (5)

20057

Lombardi Comprehensive Cancer Center at Georgetown, Washington D.C.

33612

H Lee Moffitt Cancer Center University of So Florida, Tampa

89431

Nevada Cancer Institute, Sparks

85724-5024

Arizona Cancer Center, Tuscon

03756

Dartmouth Hitchcock Medical Center, Lebanon